
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos Corp has demonstrated strong financial performance, reporting glaucoma revenue of $110 million in 3Q25, which surpassed consensus estimates and reflected a robust growth rate of 45% compared to prior quarters. The company's domestic glaucoma revenue reached $81 million, indicating a significant year-over-year increase of 57% and contributing to an improved operating margin of (7.0%), marking a notable recovery from previous periods. Additionally, Glaukos's Corneal Health segment has shown impressive growth with a compound annual growth rate of approximately 15.2% globally, further highlighting the company's positive trajectory and potential for future expansion within the ophthalmic market.
Bears say
Glaukos Corp's financial outlook is negatively affected by several factors, including a notable decline in legacy surgical glaucoma revenue, which decreased by 4.7% to $40.8 million, signaling potential stagnation in product demand. Additionally, anticipated decreases in Epioxa volumes and challenges in the Corneal Health segment suggest further material declines year-over-year, driven by a transitional phase in product adoption and reimbursement issues. Moreover, the company faces risks from slower-than-expected market growth for minimally invasive glaucoma surgery (MIGS) products, decreased uptake of its innovative iDose product, and heightened competition from new market entrants.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares